SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Beyond Meat, Inc. engages in the provision of plant-based meats. Its products include ready-to-cook meat under The Beyond Burger and Beyond Sausage brands, and frozen meat, namely, Beyond Chicken Strips and Beyond Beef Crumbles. The company was founded by Ethan Walden Brown and Brent Taylor in 2009 and is headquartered in El Segundo, CA.

Beyond Meat Inc

Beyond Meat is trending due to a potential short squeeze, fueled by high short interest and significant retail buying. The community is laser-focused on breaking key resistance levels and pushing the stock higher, with some drawing comparisons to the GME and AMC rallies of 2021. Record-breaking trading volume is adding to the frenzy as investors look to capitalize on the stock's upward momentum.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix ($NFLX) is trending down after Q3 earnings, with discussions focusing on an EPS miss attributed to a surprise Brazil tax charge, despite record revenue and viewership. The community is debating whether the dip is an overreaction or a sign of deeper valuation concerns, with some citing 'woke' content as a factor while others highlight ad revenue growth potential. Investors are actively discussing potential support levels and whether to buy the dip or anticipate further decline.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

NBIS is trending downwards, sparking heavy debate among investors about potential bottom levels and the sustainability of its valuation despite a major Microsoft deal and upcoming earnings; community sentiment is mixed, with some calling for aggressive dip buying while others express concern over the stock's persistent decline amid broader market strength. Discussions also involve the potential impact of AI spending trends and the company's diverse business segments beyond data centers.

Applied Digital Corp. is a technology company, which engages in the provision of development and operation of data centers which provide computing power. It operates through the Data Center Hosting Business and HPC Hosting Business segments. The Data Center Hosting Business segment provides energized infrastructure services to crypto mining customers. The HPC Hosting Business segment focuses on the designing, constructing, and operating data centers tailored to support high power density applications like HPC and AI. The company was founded by Wesley Carl Cummins and Jason Zhang in May 2001 and is headquartered in Dallas, TX.

Applied Digital Corporation

Applied Digital is trending amid community discussion of a major new lease agreement with a top-tier hyperscaler for AI infrastructure. While the specific tenant remains undisclosed, the potential impact of this multi-billion dollar deal on future revenue is a key talking point. Community members are also closely watching for further news and catalysts related to this deal and the broader AI sector.

Churchill Capital Corp. X is a blank check company, which was created for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded by Michael Klein on January 4, 2024 and is headquartered in New York, NY.

Churchill Capital Corp X - Ordinary Shares - Class A

Churchill Capital Corp X 

Churchill Capital Corp X ($CCCX) is trending as the stock experiences significant volatility, leading to a mix of bullish and bearish sentiment within the trading community. Discussions revolve around the recent price drop, potential support levels, and comparisons to other quantum computing stocks, with some traders viewing it as a buying opportunity while others express concerns about the SPAC structure and sector-wide pressures. Despite the turbulence, the upcoming NVIDIA GTC event and Infleqtion's involvement are focal points for potential catalysts.

Galaxy Digital, Inc. engages in digital assets and data center infrastructure, delivering solutions that accelerate progress in finance and artificial intelligence. It operates through the following segments: Digital Assets and Data Centers. The digital assets segment offers institutional access to trading, advisory, asset management, staking, self-custody, and tokenization technology. The Data Centers segment competes with a range of infrastructure providers that are building or repurposing facilities to support the rapidly growing demand for AI and compute-intensive workloads. The company was founded by Michael Novogratz in 2018 and is headquartered in New York, NY.

Galaxy Digital Inc. - Ordinary Shares - Class A

GLXY is trending amidst discussions of potential market manipulation following its earnings report, with community members expressing frustration over the stock's price action despite strong results. Some investors believe large entities are strategically driving the price down to profit from put options, while others remain optimistic about the company's long-term potential within the crypto and AI sectors.

Arcturus Therapeutics Holdings, Inc. operates as a late-stage clinical mRNA medicines and vaccine company, which engages in the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. Its products include LUNAR-COV19, LUNAR-FLU, LUNAR-OTC, and LUNAR-CF. The company was founded in 2013 and is headquartered in San Diego, CA.

Arcturus Therapeutics Holdings Inc

Arcturus Therapeutics is trending as investors discuss its potential following a significant drop and subsequent recovery, focusing on the company's progress report and financial standing. Community talking points revolve around whether the sell-off was an overreaction, with some seeing it as a buying opportunity while others express concerns about market manipulation in bio stocks. Discussions also mention institutional investor positions and potential catalysts, like upcoming trial data.

Vertiv Holdings Co. engages in the design, manufacture, and service of critical digital infrastructure technology for data centers, communication networks, and commercial and industrial environments. It also offers power management products, switchgear and busbar products, thermal management products, integrated rack systems, modular solutions, and management systems for monitoring and controlling digital infrastructure. It operates through the following geographical segments: Americas, Asia Pacific, and Europe, Middle East, and Africa (EMEA). The Americas segment offers products and services sold for applications within the data center, communication networks, and commercial and industrial markets in North America and Latin America. The Asia Pacific segment includes products and services sold for applications within the data center, communication networks, and commercial or industrial markets throughout Greater China, Australia and New Zealand, Southeast Asia, and India. The EMEA segment focuses on products and services sold for applications within the data center, communication networks, and commercial and industrial markets in Europe, Middle East, and Africa. The company was founded in 1946 and is headquartered in Columbus, OH.

Vertiv Holdings Co - Ordinary Shares - Class A

Vertiv Holdings Co

Vertiv is trending as investors digest recent Q3 earnings, which beat estimates and raised forward guidance, though the stock experienced a sharp reversal following the ER call. Community discussions revolve around speculation of a potential rug pull and market manipulation by shorts, while others see it as a buying opportunity. VRT's connection to the AI data center infrastructure boom and partnerships with companies like NVIDIA continue to be a key talking point.

GE Vernova, Inc. is a electric power industry. Its products and services generate, transfer, orchestrate, convert, and store electricity. The firm operates through the following segments: Power, Wind and Electrification. The Power segment includes design, manufacture, and servicing of gas, nuclear, hydro, and steam technologies, providing a critical foundation of dispatchable, flexible, stable, and reliable power. The Wind segment includes wind generation technologies, inclusive of onshore and offshore wind turbines and blades. The Electrification segment includes grid solutions, power conversion, electrification software, and solar and storage solutions technologies required for the transmission, distribution, conversion, storage, and orchestration of electricity from point of generation to point of consumption. The Company was founded November 09, 2021 and is headquartered in Cambridge, Massachusetts.

GE Vernova Inc.

GE Vernova is trending as traders digest the implications of strong earnings and soaring orders, particularly related to AI-driven data center demand. Despite positive results, the stock experienced volatility, leading to community discussions about market manipulation and potential buying opportunities. Some investors see GEV as a long-term play in the energy sector, while others are wary of its valuation.

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. It provides customers with access to the company’s quantum computing systems via the cloud in the form of quantum computing as a service. It offers professional services such as customer assistance in identifying and implementing quantum-computing applications. The company was founded on January 25, 2022 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

D-Wave Quantum (QBTS) is experiencing volatility as the community debates its valuation and future prospects, with some suggesting it's overhyped while others see long-term potential. Discussion includes potential shakeouts, institutional buying, and the impact of broader market factors like rate cuts. Some traders are taking short positions, while others remain bullish, awaiting news catalysts and government contracts.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul><li>The company said that treatment-related adverse events were observed in the study for the first few doses but ceased with continuous dosing.</li><li>The Data Monitoring Committee found no convincing evidence that the serious adverse event is related to ARCT-032 and approved the study to proceed. &nbsp;</li></ul>Arcturus Therapeutics Holdings (ARCT) on Wednesday announced interim results from a mid-stage trial of its ARCT-032 therapy in people with cystic fibrosis.In a cohort of the study, six patients with cystic fibrosis received inhaled 10 mg doses of ARCT-032 daily over 28 days.<h2 class="st-heading-2">What’s Driving Down The Stock?</h2>The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.arcturusrx.com/news-releases/news-release-details/arcturus-therapeutics-provides-interim-phase-2-data-cystic">reported</a> that treatment-related adverse events were observed in the study during the initial doses but ceased with continuous dosing.However, the Data Monitoring Committee found no convincing evidence that the serious adverse event is related to ARCT-032 and approved the study to proceed, the company said. One treatment-related adverse event also occurred in a participant after the end of the dosing period, it said. Furthermore, the treatment was generally safe and well-tolerated, the company added.However, shares of the company fell 58% on Wednesday. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/ARCT">ARCT stock</a> rose from ‘bearish’ to ‘extremely bullish’ over the past 24 hours, while message volume rose from ‘low’ to ‘high’ levels.<h2 class="st-heading-2">What Are The Firm’s Plans Ahead?</h2>Arcturus noted on Wednesday that an expanded third cohort is ongoing. The company aims to enroll up to six subjects in the cohort if there is a dose escalation response at 15 mg and if ARCT-032 continues to be generally safe and well-tolerated.The company also said that it intends to kickstart a 12-week safety and preliminary efficacy study in up to 20 cystic fibrosis participants in the first half of 2026.Cystic fibrosis (CF) is an inherited genetic disorder that causes thick, sticky mucus to build up in the body's organs, primarily affecting the lungs and pancreas. It is caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.<blockquote>“We are particularly encouraged by the early signals of mucus plug reduction in Class I CF participants treated with ARCT-032 because Class I CF individuals do not produce CFTR and therefore do not respond to available CFTR modulator therapy.”— Juergen Froehlich, Chief Medical Officer, Arcturus</blockquote>ARCT stock is down 43% this year and 51% over the past 12 months.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-to-recall-nearly-13000-vehicles-in-us/cLG57HOR3q4">Tesla To Recall Nearly 13,000 Vehicles In US, But Retail Has Its Eyes Set On Q3 Earnings</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Medical syringe is seen with Arcturus Therapeutics company logo displayed on a screen in the background in this illustration photo taken in Poland on June 16, 2020. (Photo Illustration by Jakub Porzycki/NurPhoto via Getty Images)

Arcturus Therapeutics Stock Plunges Over 58% Today: What’s Causing The Sell-Off?

The company said that treatment-related adverse events were observed in the study for the first few doses but ceased with continuous dosing.

Equity

Zacks.com featured highlights include Flux Power, Aura Minerals, Arcturus Therapeutics and Sterling Infrastructure

Flux Power, Aura Minerals, Arcturus Therapeutics, and Sterling Infrastructure show strong price momentum amid market uncertainty.

Arcturus Therapeutics (ARCT) Moves 7.7% Higher: Will This Strength Last?

Arcturus Therapeutics (ARCT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

4 Stocks With Recent Price Strength to Maximize Your Gains

FLUX, AUGO, ARCT and STRL are showing notable price strength amid a volatile market.

Are Medical Stocks Lagging  Aquestive Therapeutics (AQST) This Year?

Here is how Aquestive Therapeutics (AQST) and Arcturus Therapeutics (ARCT) have performed compared to their sector so far this year.

Arcturus Therapeutics (ARCT) is on the Move, Here's Why the Trend Could be Sustainable 

Arcturus Therapeutics (ARCT) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

Recursion Pharmaceuticals (RXRX) Surges 8.2%: Is This an Indication of Further Gains?

Recursion Pharmaceuticals (RXRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Arcturus Therapeutics (ARCT) Surges 8.7%: Is This an Indication of Further Gains?

Arcturus Therapeutics (ARCT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Should You Buy Arcturus Therapeutics (ARCT) After Golden Cross?

Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?

Arcturus Therapeutics (ARCT) Reports Q2 Loss, Tops Revenue Estimates

Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of +69.37% and +20.84%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Will Netflix ($NFLX) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

) beat quarterly earnings? 
 
*Powered by Polymarket

ARCT
Arcturus Therapeutics Holdings Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest ARCT News

ARCTArcturus Therapeutics Holdings Inc